A real-world study to evaluate the efficacy, tolerability, and tolerability of silver-containing dressings based on lipid hydrogel technology in the treatment of superficial partial-thickness burns of the skin

开始日期2025-01-01

申办/合作机构

海军军医大学第一附属医院

NCT06629558

/ RecruitingN/AIIT

Efficacy and Safety of 0.5% w/v Nano- Silver Nitrate Versus Silver Nitrate Solution for Bronchoscopic Lung Volume Reduction in Management of Localized Emphysema: Prospective Interventional Randomized Controlled Clinical Trial

Emphysema is a progressive phenotype of chronic Obstructive Pulmonary Disease (COPD), poses a significant global health burden characterized by irreversible lung parenchymal destruction and airspace enlargement.
In recent years, bronchoscopic lung volume reduction (BLVR) has considerable interest as a minimally invasive approach to reducing hyperinflation and improving lung function in patients with emphysema.
BLVR techniques aim to achieve lung volume reduction by occluding or ablating emphysematous lung tissue through endobronchial delivery of various agents. Many techniques are available for BLVR as coil, endo-bronchial valve, and biological as thrombin, autologous blood and chemicals as silver nitrate solution.

开始日期2024-10-01

申办/合作机构

Mansoura University Hospital

CTRI/2024/06/068709

/ Not yet recruitingN/AIIT

Indirect Pulp Treatment In Young Permanent Molars: 38% Silver Diamine Fluoride (SDF) with and without light cure- A Clinical Control Trial - NIL

开始日期2024-06-22

申办/合作机构-

100 项与硝酸銀相关的临床结果

登录后查看更多信息

100 项与硝酸銀相关的转化医学

登录后查看更多信息

100 项与硝酸銀相关的专利（医药）

登录后查看更多信息

66,487

项与硝酸銀相关的文献（医药）

2025-07-01·Separation and Purification Technology

Synthesis of hydrochar-based AgBr/Bi2WO6 heterojunction photocatalyst using dopant element and its loading on PVDF membrane: Study on degradation of sulfadiazine

作者: Xie, Xiaoyun ; Dong, Wenrui ; Yang, Baocheng ; Qi, Kemin ; Zhang, Leilei ; Wang, Zhaowei ; Hu, Jiani ; Mao, Mianqi

Environmentally friendly bismuth-based photocatalysts and biomass carbon materials are attractive in photocatalysis but also face the problem of fast photogenerated carrier complexation.To cope with this problem and forming tighter heterojunctions, this manuscript presented the synthesis of Bi₂WO_6/AgBr heterojunction photocatalyst loaded with Ag nanoparticles (Ag NPs) supported by hydrochar, which was synthesized by using Br^- doped in Bi₂WO₆, resulting in an excellent photocatalytic effect.The heterojunction, the Ag NPs, and the abundance of oxygenated functional groups (OFGs) of hydrochar (CHC) all served to enhance the photogenerated carrier separation performance of Ag/AgBr/Bi₂WO₆/CHC (AABC).Furthermore, the polyfuran structure presented in CHC might accelerate the generation of photogenerated carriers, thus also promoting the ability of AABC to sep. photogenerated carriers.This enabled AABC to degrade 97.58% of sulfadiazine (SD) in 90 min while exhibiting a pseudo-first-order kinetic constant more than 12 times that of pure Bi₂WO₆.Remarkably, AABC exhibited extraordinary reusability, environmental adaptability, and generalizability to different types of organic pollutants.After five cycles, the SD removal was maintained at 94.62% and the total organic carbon (TOC) removal rate of 78.27% was achieved in 150 min.The PVDF/AABC membrane, prepared by loading AABC, was observed to degrade 90.03% of SD within 200 min of visible light irradiationThis work enabled the utilization of the dopant Br^- in Bi₂WO₆, providing new ideas for the design of efficient photocatalysts and their application in antibiotic water treatment, as well as new insights into the reuse of waste biomass.

2025-07-01·Separation and Purification Technology

Modulation of bismuth vacancies on BiOCl surface by tungsten doping for photocatalytic nitrogen reduction

作者: Xiang, Yulong ; Dong, Xiaoli ; Wang, Yu ; Niu, Jialin ; Zheng, Nan ; Liu, Chundong

Photocatalytic nitrogen (N₂) reduction reaction for solar energy conversion encounters considerable challenges due to the inadequate performance of semiconductor photocatalysts.The role of metal cation vacancies in photocatalytic nitrogen fixation is rarely explored.Here, we report a facile strategy to construct BiOCl nanosheets with tunable Bi-vacancy via tungsten doping.W-doped energy levels and Bi vacancies (V_Bi) can effectively tune the energy band structure of BiOCl, thereby broadening the range of light absorption and enhancing carrier transport.D. functional theory (DFT) calculation results reveal that the doped W⁶⁺ can act as the main activation sites of nitrogen for N≃N elongation, and the Bi vacancies are the main adsorption sites with the strongest nitrogen adsorption energy.This results in the formation of dual active sites for nitrogen adsorption and activation.W-BiOCl-2 showed excellent nitrogen fixation efficiency of 1016.6 μmol h^-1 g^-1, which was 2.6 times higher than that of pristine BiOCl without any sacrificial agents.This study provides a promising strategy for the design of high-performance photocatalytic N₂ fixation catalysts with multiple active sites.

2025-07-01·Separation and Purification Technology

Capturing and converting CO2 using amino acids as various commercially valuable nano-carbonates

作者: Xing, Malcolm ; Li, Qingyang ; Qian, Yong ; Li, Bingyun

Carbon dioxide (CO₂) is the most significant greenhouse gas and one of the strategies to reduce CO₂ emission is to convert CO₂ into com. valuable products.Currently, methods that can effectively capture and convert CO₂ into carbonate nanomaterials, which have unique applications in various fields, have rarely been reported, and there are no universal methods that can capture and convert CO₂ into different nano-carbonates.In this study, an innovative two-step strategy based on amino acids was developed to produce multiple different carbonate nanoparticles, including CaCO₃, BaCO₃, and Ag₂CO₃ nanoparticles with diameters of 70 nm, 50 nm, and 7 nm, resp.Fundamentally important, the NMR data clearly demonstrated that it was the amino acids (e.g., glycine) that dictated the formation of carbonate nanoparticles.In the presence of amino acids, a competition in forming nanoparticles and microparticles was observed, and the formation of nanoparticles was proportional to the carbamate formed from CO₂ reacting with amino acids.In the absence of amino acids, carbonate microparticles (∼ 2μm) were formed.

项与硝酸銀相关的新闻（医药）

2024-04-16

·PRNewswire

Journal of the American Chemical Society Differentiates EVŌQ Nano's EVQ-218 Nanoparticle as a New Form of Silver; Holds Promise for Widespread Medical Applications

EVQ-218 is the first stable, nonemissive, pure metal nanoparticle on par with NIST standards for ideal materials. The 'clean and green' EVQ-218 nanosilver is free of toxic ion emissions. SALT LAKE CITY, April 16, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, materials, and textile science industries, today announced that the American Chemical Society journal, ACS Omega, published a peer-reviewed study characterizing and differentiating the company's lead asset, EVQ-218, as a new form of silver nanoparticle (AgNP). EVQ-218 meets the highest standards set by the National Institute of Standards and Technology (NIST) while avoiding the limitations and safety risks of other nanosilvers. Continue Reading Engineered by EVŌQ Nano, EVQ-218 is the first and only stable, non-ionic silver nanoparticle (AgNP) for medical applications. The characterization of EVQ-218 is timely as the rise of antimicrobial resistance (AMR) has caused a surge of research into safer, more effective treatments. Prioritized by the World Health Organization as one of the top 10 global public health threats, AMR threatens the effective prevention and treatment of infections.1 "The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs," said Shaun Rothwell, EVŌQ Nano CEO. While silver's antibacterial qualities have been known for centuries,2,3 it is widely established that the antimicrobial activity is due to ion emission, which poses toxicity risks for biomedical and consumer product applications.4-7 Realizing Silver's Therapeutic Potential Compared to traditional nanosilvers, EVQ-218 is differentiated due to its characterization and behavior as the first stable, nonemissive, pure silver nanoparticle that is on par with NIST standards for ideal materials, making it a superior candidate for biomedical and consumer product use.8 "Not only does EVQ-218 match NIST's standards for particle size and shape, but it possesses an ultrastable shell structure that completely inhibits ion emission — a first for a pure metal nanoparticle," said Bretni Kennon, Ph.D., principal investigator, EVŌQ Nano. Novel Mechanism of Action EVQ-218's antimicrobial efficacy is rooted in its ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This blocks activation of bacterial mutations that contribute to AMR. In contrast, nanosilvers with ions rupture cell walls, triggering activation of AMR pathways. Multi-Patented Laser Nanofabrication Process EVQ-218 is a high-energy produced silver nanoparticle with a method of manufacture that avoids chemical or biological synthesis. Ablation via a multiple, cross-laser system occurs at temperatures and pressures akin to diamond formation. The patented single-step, high-volume laser process generates stable, pure metal nanoparticles directly into pharmaceutical-grade water.8 The sub-10 nm spherical nanoparticles have an ultrastable shell structure that inhibits the hallmark ion emission that occurs in other nanosilver species.8 The resulting particle size and shape characteristics prevent the need for stabilizing chemistries.8 When factoring in shelf life, EVQ-218 maintains uniform stability for years; traditional nanosilvers degrade within weeks.8 These properties make EVQ-218 an attractive clean and green alternative to traditional nanosilvers.8 Advancing Antimicrobial Solutions With EVQ-218 To address the critical issue of healthcare-associated infections (HAIs), primarily caused by indwelling devices like catheters, EVŌQ Nano is collaborating with leading catheter manufacturers. By infusing EVQ-218 throughout the polymer, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.9 EVŌQ Nano has also received two grants from the Cystic Fibrosis Foundation for the development of an inhaled therapeutic to treat pulmonary bacterial infections. The company had its Pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) in March and, with the agency's feedback, is confidently advancing toward Phase I clinical trials. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates uniform, sub-10 nm nanoparticles with distinct surface chemistry. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Walsh TR, Gales AC, Laxminarayan R, Dodd PC. Antimicrobial resistance: addressing a global threat to humanity. PLoS Med. 2023 Jul 3;20(7):e1004264. doi: 10.1371/journal.pmed.1004264. PMID: 37399216; PMCID: PMC10317217. Alexander JW. History of the medical use of silver. Surg Infect. 2009;10(3):289. Medici S, Peana M, Nurchi VM, Zoroddu MA. Medical uses of silver—history, myths, and scientific evidence. J Med Chem. 2019;62:5923−5943. Stabryla LM, Johnston KA, Millstone JE, Gilbertson LM. Emerging investigator series: it's not all about the ion: support for particle-specific contributions to silver nanoparticle antimicrobial activity Environ Sci Nano. 2018;5:2047−2068. Kedziora A, Speruda M, Krzyzewska E, Rybka J, Bugla-Ploskonska G. Similarities and differences between silver ions and silver in nanoforms as antibacterial agents. Int J Mol Sci. 2018;19:444. Slavin YN, Asnis J, Häfeli UO, Bach H. Metal nanoparticles: understanding the mechanisms behind antibacterial activity. J Nanobiotechnology. 2017;15:65. Liao C, Li Y, Tjong SC. Bactericidal and cytotoxic properties of silver nanoparticles. Int J Mol Sci. 2019;20:449. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024;9(7):7891-7903. doi: 10.1021/acsomega.3c07745. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. . SOURCE EVOQ Nano

2024-04-08

·Mass Device

Orthobond wins FDA de novo approval for antibacterial technology that could have vast device applications

The Monmouth Junction, New Jersey-based device developer says it’s the first time the FDA has granted a de novo request for a non-eluting coating designed to actively kill bacteria that could contaminate the surface of a medical device. Orthobond was founded by Princeton University Chemistry Professor Emeritus Jeffrey Schwartz and the late Dr. Gregory Lutz, who was physiatrist-in-chief emeritus at the Hospital for Special Surgery. Lutz died of cancer on March 5, but knew FDA approval was on the horizon. Orthobond CEO David Nichols called the FDA approval a “testament to Gregory’s legacy” in a statement shared with MassDevice. “We are proud to be able to carry it on into this next chapter.” The first application will be Ostaguard-treated SeaSpine Mariner pedicle screws, according to FDA records. Those could be used in patients early next year, Nichols (a former Zimmer Biomet executive) said in an exclusive interview with MassDevice. Orthobond’s proprietary technology is a quaternary ammonium compound coating that’s highly effective in neutralizing the different bacteria responsible for most device-related infections and can be applied to almost any device, he said. Medical Design & Outsourcing: How Orthobond’s antimicrobial coating prevents contamination of medical devices Unlike antibiotic-eluting devices, Ostaguard doesn’t use antibiotics so there’s no risk of creating drug-resistant superbugs. And while antimicrobial materials like silver, palladium and copper can kill bacteria, those toxic metals aren’t biocompatible with human tissue, Nichols said. “Those have been the barriers for decades,” he said. “[Ostaguard] is a brand new category for the FDA. It doesn’t come off the device — it is considered a device — and it actively kills bacteria.” The FDA gave the new category a generic name of “spinal fusion device with quaternary ammonium compound coating,” defined as “a rigid metallic implant device or system comprised of single or multiple components intended to facilitate fusion in skeletally mature patients. The device includes a quaternary ammonium compound coating that is covalently bonded to the device. Where applied, the coating is intended to reduce microbial contamination on the surface of the device prior to implantation. The device does not contain antimicrobial agents that act within or on the body and this device type does not include combination products.” According to an approval letter shared by Ostaguard, the FDA classified the product as a Class II device and established special controls, which Orthobond declined to divulge. While Orthobond said it found no evidence of local or systemic toxicity in sheep, guinea pig and canine testing, the coating technology has not been evaluated in human clinical trials. Orthobond says the technology’s intellectual property is protected through 2037 through three patent fences covering the covalent surface chemistry, antimicrobial layer and analytical processes, including 27 patents and 12 pending applications. Orthobond intends to seek 510(k) clearances for additional orthopedic spinal implant indications before expanding to other fields such as joint reconstruction, oncology, sports medicine, plastic surgery and cardiovascular. “We’re working on a neuromodulation device, there’s a trauma device we’re working on, and we’re going to work on a cochlear implant,” Nichols said. “If you use a cochlear implant and it gets infected, you pretty much lose your hearing. That’s something that they want to solve.” “We’d like to be as broad as possible,” he continued. “… This should be on all devices that get used. There’s no reason why not. If you’re going to sterile package them, why don’t you put an antibacterial on them?” Beyond medtech, Orthobond leaders believe the technology could also have commercial and industrial applications in areas such as automotive, consumer products and textiles. about how Orthobond’s Ostaguard antibacterial technology works and additional potential applications at our sister site, Medical Design & Outsourcing.

上市批准

2024-02-22

·PRNewswire

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 Billion Catheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ -- EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world's leading pathogens implicated in healthcare-associated infections (HAIs), which are some of the most common complications of hospital care. More than 1 million HAIs occur annually in the U.S., causing significant morbidity and mortality. The majority of HAIs are associated with indwelling devices, with catheter-associated urinary tract infections (CAUTIs) representing the most common type.1 Rising antimicrobial resistance has compounded this health threat — as up to one-third of CAUTIs in the U.S. are drug resistant,2 with annual treatment cost exceeding $13 billion.3 "For nearly 30 years, companies have tried to create antimicrobial devices, but the performance never proved effective. Our nanoparticle technology represents an exciting innovation that could profoundly reduce infections associated with medical devices like catheters without contributing to antibiotic resistance," said Shaun Rothwell, CEO of EVŌQ Nano. "With its proven ability to resist microbial growth and biofilm formation without triggering antimicrobial resistance, this platform has the potential to significantly impact device-related infections — much like the antibiotic revolution transformed infectious disease treatment a century ago." By infusing EVŌQ Nano's proprietary nanoparticle, EVQ-218, throughout the polymer itself, medical devices are extrinsically equipped with antimicrobial protection that has proven to be effective against the most prevalent pathogenic microorganisms. The company is currently targeting the $29 billion catheter market, expected to reach $50 billion by 2031.4 Strong Antimicrobial Efficacy In collaboration with the world's leading catheter manufacturers, extensive lab testing on catheters, luers, and fittings manufactured with EVŌQ Nano's EVQ-218 nanoparticle infused throughout the polymer, demonstrated: Strong antibacterial, antifungal, and antibiofilm efficacy Staphylococcus aureus: 7-8 log reduction Pseudomonas aeruginosa: 6-7.5 log reduction Candida albicans: 5-6.5 log reduction Broad-spectrum activity against 64 bacterial strains tested No degradation of antimicrobial activity; sustained presence for the life of the product Novel Mechanism of Action Existing antimicrobial solutions for medical devices have fallen short. Coatings slough off, degrade over time, and can only be applied to limited materials. While silver is a proven and powerful antimicrobial, current antibacterial catheters externally coated with silver lose efficacy once inserted due to natural sloughing of the material coupled with the short life of silver ions. This combination hinders the antimicrobial activity of current products. EVQ-218 is the first and only non-ionic silver nanoparticle. Extensive studies characterize EVQ-218 as a new form of silver nanoparticle (AgNP), manufactured with EVŌQ Nano's multi-patented nanofabrication process that requires only laser energy, ultrapure water, and pure silver metal.5 Unlike standard silver nanoparticles, EVQ-218 has true "bare" silver surface chemistry, with greater group stability that mitigates the need for added stabilizers.5 The discovery and development of a non-ionic silver nanoparticle represents a pivotal innovation, unlocking the full therapeutic potential of silver without its detrimental trade-offs. EVQ-218 delivers high antimicrobial efficacy without ion emissions.6,7 Its efficacy is rooted in EVQ-218's ability to disrupt bacteria's metabolic processes without triggering antimicrobial resistance. EVQ-218 stops bacterial growth by sequestering sulfur. The sequestration of sulfur inhibits metabolic activity within the bacterial cell without compromising cell structures or lysing the cell wall. This avoids activation of bacterial mutations that contribute to antimicrobial resistance. In contrast, nanoparticles with silver ions rupture cell walls, triggering activation of resistance pathways. By incorporating antimicrobial protection into the material manufacturing process, EVŌQ Nano's technology enables the next generation of medical devices to more effectively guard against disease. About EVŌQ Nano EVŌQ Nano is a nanoscience company that engineers novel nanoparticles for the life science, materials science, and textile science industries. The company's multi-patented, high-volume laser nanofabrication process creates nanoparticles that are uniformly sized, surfactant-free, with consistent spherical morphology, and no ion emissions under standard and stressed conditions. These properties represent a significant advancement in nanoscience with the potential for a wide range of applications. To learn more, visit evoqnano.com. Media Contact Capwell Communications [email protected] References Health Care-Associated Infections. Patient Safety Network. Published September 7, 2019. Accessed November 21, 2023. Werneburg GT. Catheter-associated urinary tract infections: current challenges and future prospects. Res Rep Urol. 2022; Apr 4;14:109-133. doi: 10.2147/RRU.S273663. PMID: 35402319; PMCID: PMC8992741 Estimating the additional hospital inpatient cost and mortality associated with selected hospital-acquired conditions. Agency for Healthcare Research and Quality. Content last reviewed November 2017. Accessed January 19, 2024. Darandale M, Talekar D, Deshmukh R. Catheters Market Research, 2031. Allied Market Research. Published May 2022. Accessed December 6, 2023. Kennon BS, Niedermeyer WH. EVQ-218: Characterization of high-energy nanoparticles that measure up to NIST standards. ACS Omega. 2024. doi: 10.1021/acsomega.3c07745 Niedermeyer W, inventor; ATTOSTAT Inc., assignee. Method and apparatus for production of uniformly sized nanoparticles. US patent 9,849,512. November 9, 2017. Dimpka CO, Calder A, Gajjar P, Merugu S, Huang W, Britt DW, McLean JE, Johnson WP, Anderson AJ. Interaction of silver nanoparticles with an environmentally beneficial bacterium, Pseudomonas chlororaphis. J. Haz. Mat. 2011; 188:428-435. doi: 10.1016/j.jhazmat.2011.01.118 SOURCE EVŌQ Nano

100 项与硝酸銀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01730	-	D08AL01	DB11080

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疣	澳大利亚	Sutherland Medical Pty Limited	2016-07-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05130814 (RISE_UP, CTgov)	N/A	褥疮	48	bandage+zinc+hyaluronic acid gauze plus polyurethane foam+hyaluronic acid sodium salt+metallic silver (Control Group)	遞艱鏇艱鏇願網齋糧觸(構衊壓憲選簾糧壓製蓋) = 鑰衊遞築簾鹹積鬱齋壓餘遞餘觸鬱淵顧鑰獵鑰 (選觸壓獵壓築淵淵繭遞, 繭願網壓積顧簾製獵膚 ~ 範構齋膚膚艱選廠窪壓) 更多	-	2025-01-28
				bandage+zinc+hyaluronic acid gauze plus polyurethane foam+hyaluronic acid sodium salt+metallic silver (EmoLED Group)	遞艱鏇艱鏇願網齋糧觸(構衊壓憲選簾糧壓製蓋) = 鹹製簾觸鏇築衊獵壓遞餘遞餘觸鬱淵顧鑰獵鑰 (選觸壓獵壓築淵淵繭遞, 鬱築簾窪齋鹹淵齋築齋 ~ 鏇壓鹹憲壓繭獵糧願膚) 更多
NCT02519738 (CTgov)	临床3期	化脓性肉芽肿	52	Silver Nitrate (Silver Nitrate)	鏇鹽顧選簾製鹽艱膚簾(遞選糧蓋糧齋餘淵鬱鏇) = 鏇壓淵製鑰鏇築鑰顧積遞窪構遞繭衊窪蓋積積 (艱齋醖蓋遞糧網鑰醖製, 築餘網遞構壓醖範壓範 ~ 範觸膚艱憲醖製選齋廠) 更多	-	2022-01-25
				Kenalog (Triamcinolone) (Kenalog (Triamcinolone))	鏇鹽顧選簾製鹽艱膚簾(遞選糧蓋糧齋餘淵鬱鏇) = 艱網選醖網齋鬱顧襯壓遞窪構遞繭衊窪蓋積積 (艱齋醖蓋遞糧網鑰醖製, 製醖膚製衊廠選築壓衊 ~ 憲糧鏇齋製鏇淵醖獵壓) 更多
AACR2020	N/A	多形性胶质母细胞瘤	-	Silver nanoparticles	繭網鹹窪積襯獵鹹憲鏇(壓選積繭鹹蓋壓艱鏇構) = 積鏇鑰觸憲網艱膚糧網範範築鏇築窪範壓構窪 (衊獵糧齋築膚網範繭鑰 )	积极	2020-08-15
				Silver nanoparticles + low-level He-Ne laser	繭網鹹窪積襯獵鹹憲鏇(壓選積繭鹹蓋壓艱鏇構) = 願簾鹹艱遞壓積構繭顧範範築鏇築窪範壓構窪 (衊獵糧齋築膚網範繭鑰 )
ERS2016	N/A	气肿	12	Silver Nitrate solution 0.5%	(廠簾鏇衊廠遞顧觸膚鏇) = 鏇鹽範製繭選鹽網選構糧範膚獵遞製蓋淵艱願 (淵積範繭顧鬱築淵構簾 ) 更多	积极	2016-09-01
ACTRN12609000451202 (Pubmed \| J Burn Care Res)	临床3期	烧伤	89	Silver-Based Burns Dressing	顧醖築窪願襯鏇製憲艱(鹽範餘願憲窪簾簾膚鏇) = 糧壓簾遞積醖網簾襯窪鬱窪齋獵觸夢範鹹艱繭 (顧築觸範窪構鏇夢鬱遞 )	-	2016-01-01
				Silver-Based Burns Dressing	顧醖築窪願襯鏇製憲艱(鹽範餘願憲窪簾簾膚鏇) = 膚糧鬱醖繭膚憲餘鑰衊鬱窪齋獵觸夢範鹹艱繭 (顧築觸範窪構鏇夢鬱遞 )
NCT00675922 (Soaks, CTgov)	临床2/3期	烧伤	98	Sulfamylon (Percent Infections:Sulfamylon Site)	壓鬱觸願齋糧鏇積製鏇(遞淵齋鹽獵繭壓範膚艱) = 蓋構願鹹壓積蓋遞衊鏇壓齋簾築齋願襯觸鏇鬱 (選繭憲襯積餘膚願廠鏇, 衊壓鏇獵網憲廠觸鏇艱 ~ 選膚醖繭鬱顧遞選醖簾)	-	2013-01-18
				Silver Nitrate (Percent Infections: Silver Nitrate Site)	壓鬱觸願齋糧鏇積製鏇(遞淵齋鹽獵繭壓範膚艱) = 艱網糧膚簾齋醖繭遞顧壓齋簾築齋願襯觸鏇鬱 (選繭憲襯積餘膚願廠鏇, 醖餘窪夢鏇夢蓋廠簾製 ~ 製衊積鏇衊築窪糧憲窪)